Stocks · News reference
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
Read original at benzingaORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees as inducement for employment. The grants were approved by the Compensation Committee and comply with Nasdaq Rule 5635(c)(4). The company continues development of its clinical-stage oncology candidates including rinzimetostat for prostate cancer and enozertinib for NSCLC.
Read original at globenewswire-incFiled: 2026-08-03 AccNo: 0001193125-26-330568 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar